



MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

**Proteon Therapeutics Receives Issued U.S. Patent  
Broadly Covering New Method of Artery and Vein Dilation**

For Immediate Release

WALTHAM, Massachusetts and Kansas City, Missouri (January 23, 2007) – Proteon Therapeutics, Inc. announced today that a key patent has been issued by the United States Patent and Trademark Office (USPTO). This U.S. patent (No. 7,153,505) broadly covers the use of a class of proteins known as elastases for dilating arteries and veins in humans. Proteon Therapeutics owns the issued patent, after receiving an assignment of the underlying technology from Johns Hopkins University. Dr. Stephen S. Rabinowitz of Fried, Frank, Harris, Shriver, and Jacobson served as lead patent counsel for the application.

“The issuance of this additional patent adds substantially to Proteon’s IP estate in elastase vasodilation, which is instrumental to the development and commercialization of PRT-201,” said Timothy Noyes, President and Chief Executive Officer of Proteon Therapeutics.

**About Proteon Therapeutics**

**Proteon Therapeutics**, Inc is a privately held biotechnology company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. The company’s venture capital investors include TVM Capital ([www.tvm-capital.com](http://www.tvm-capital.com)), Skyline Ventures ([www.skylineventures.com](http://www.skylineventures.com)), Prism VentureWorks ([www.prismventure.com](http://www.prismventure.com)) and Intersouth Partners ([www.intersouth.com](http://www.intersouth.com)). For more information about Proteon, visit [www.proteontherapeutics.com](http://www.proteontherapeutics.com).

**COMPANY CONTACT:**

F. Nicholas Franano  
Chief Scientific Officer  
816-531-0028

[nfranano@proteontherapeutics.com](mailto:nfranano@proteontherapeutics.com)

**PRESS CONTACT:**

Holly Gibson  
Fleishman Hillard  
816-512-2349

[gibsonh@fleishman.com](mailto:gibsonh@fleishman.com)